![]() |
MK-2206
- 英文名称:MK-2206
- 品牌:WYTSCI
- 产地:进口
- 型号:1MG
- 货号:WT-AY-B11412
- cas:1032350-13-2
- 价格: ¥1/mg
- 发布日期: 2025-04-10
- 更新日期: 2025-04-30
产品详请
产地 | 进口 |
品牌 | WYTSCI |
货号 | WT-AY-B11412 |
用途 | 科研检测 |
英文名称 | MK-2206 |
包装规格 | 1MG |
CAS编号 | 1032350-13-2 |
别名 | MK-2206 |
纯度 | 98+% |
分子式 | |
是否进口 | 是 |
纯度:98% by HPLC,;NMR (Conforms)
分子式:C25H21N5O·2HCl
分子量:480.39
溶剂:DMSO (10 mg/ml)
性状:Yellow solid
存储:-20°C
Activity (short version):Potent and selective AKT inhibitor
Function / Pharmacology:MK-2206 is a potent and selective allosteric inhibitor of Akt (IC50’s: Akt1 = 5 nM, Akt2 = 12 nM, Akt3 = 65 nM) that enhances the in vitro and in vivo antitumor efficacy of several standard chemotherapeutic agents.1 It was able to decrease insulin-stimulated glucose uptake, glycogen synthesis and glycogen synthase activity in rat muscle.2 MK-2206 induced G1-phase cycle arrest and sensitized HepG2 hepatocellular carcinoma cells to TRAIL-induced apoptosis.3
分子式:C25H21N5O·2HCl
分子量:480.39
溶剂:DMSO (10 mg/ml)
性状:Yellow solid
存储:-20°C
Activity (short version):Potent and selective AKT inhibitor
Function / Pharmacology:MK-2206 is a potent and selective allosteric inhibitor of Akt (IC50’s: Akt1 = 5 nM, Akt2 = 12 nM, Akt3 = 65 nM) that enhances the in vitro and in vivo antitumor efficacy of several standard chemotherapeutic agents.1 It was able to decrease insulin-stimulated glucose uptake, glycogen synthesis and glycogen synthase activity in rat muscle.2 MK-2206 induced G1-phase cycle arrest and sensitized HepG2 hepatocellular carcinoma cells to TRAIL-induced apoptosis.3